公开(公告)号：US20120164129A1

公开(公告)日：2012-06-28

申请号：US13331109

申请日：2011-12-20

申请人： Enrico Di Cera ,  Andras Gruber ,  Prafull Gandhi ,  Leslie Pelc ,  Nicola Pozzi ,  David Collier Wood

发明人： Enrico Di Cera ,  Andras Gruber ,  Prafull Gandhi ,  Leslie Pelc ,  Nicola Pozzi ,  David Collier Wood

IPC分类号： A61K38/48 ,  C12N9/74 ,  A61P7/02

CPC分类号： C12N9/6429 ,  A61K38/4833 ,  C12Y304/21005 ,  Y02A50/473

摘要： One aspect of the invention contemplates a mutant E-WE thrombin precursor that contains the SEQ ID NO:1 amino acid residue sequence. Another aspect contemplates a thrombin precursor that contains the amino acid residue sequence Asp/Glu-Gly-Arg at positions 325, 326 and 327 based on the preprothrombin sequence. A third aspect contemplates a thrombin precursor that contains the SEQ ID NO:1 amino acid residue sequence as well as the amino acid residue sequence Asp/Glu Gly Arg at positions 325, 326 and 327 based on the preprothrombin sequence. Also contemplated is a composition that contains an effective amount of mutant thrombin dissolved or dispersed in a pharmaceutically acceptable carrier. A method is also disclosed for enhancing treating and preventing thrombosis in a mammal in need using that composition.

摘要翻译： 本发明的一个方面考虑了含有SEQ ID NO：1氨基酸残基序列的突变E-WE凝血酶前体。 另一方面考虑了基于前凝血酶原序列在325,326和327位含有氨基酸残基序列Asp / Glu-Gly-Arg的凝血酶前体。 第三方面考虑了基于前凝血酶原序列的含有SEQ ID NO：1氨基酸残基序列以及位置325,326和327的氨基酸残基序列Asp / Glu Gly Arg的凝血酶前体。 还考虑了包含溶解或分散在药学上可接受的载体中的有效量的突变凝血酶的组合物。 还公开了一种用于增强使用该组合物治疗和预防需要的哺乳动物血栓形成的方法。

公开(公告)号：US08940297B2

公开(公告)日：2015-01-27

申请号：US13331109

申请日：2011-12-20

申请人： Enrico Di Cera ,  Andras Gruber ,  Prafull Gandhi ,  Leslie Pelc ,  Nicola Pozzi ,  David Collier Wood

发明人： Enrico Di Cera ,  Andras Gruber ,  Prafull Gandhi ,  Leslie Pelc ,  Nicola Pozzi ,  David Collier Wood

IPC分类号： C12N9/74 ,  A61K38/48

CPC分类号： C12N9/6429 ,  A61K38/4833 ,  C12Y304/21005 ,  Y02A50/473

摘要： One aspect of the invention contemplates a mutant E-WE thrombin precursor that contains the SEQ ID NO:1 amino acid residue sequence. Another aspect contemplates a thrombin precursor that contains the amino acid residue sequence Asp/Glu-Gly-Arg at positions 325, 326 and 327 based on the preprothrombin sequence. A third aspect contemplates a thrombin precursor that contains the SEQ ID NO:1 amino acid residue sequence as well as the amino acid residue sequence Asp/Glu Gly Arg at positions 325, 326 and 327 based on the preprothrombin sequence. Also contemplated is a composition that contains an effective amount of mutant thrombin dissolved or dispersed in a pharmaceutically acceptable carrier. A method is also disclosed for enhancing treating and preventing thrombosis in a mammal in need using that composition.

摘要翻译： 本发明的一个方面考虑了含有SEQ ID NO：1氨基酸残基序列的突变E-WE凝血酶前体。 另一方面考虑了基于前凝血酶原序列在325,326和327位含有氨基酸残基序列Asp / Glu-Gly-Arg的凝血酶前体。 第三方面考虑了基于前凝血酶原序列的含有SEQ ID NO：1氨基酸残基序列以及位置325,326和327的氨基酸残基序列Asp / Glu Gly Arg的凝血酶前体。 还考虑了包含溶解或分散在药学上可接受的载体中的有效量的突变凝血酶的组合物。 还公开了一种用于增强使用该组合物治疗和预防需要的哺乳动物血栓形成的方法。